2015-06-03 18:57:20 UTC

New Developments in Hepatitis B

Clinical Snapshots


This AGA Clinical Snapshot is an executive summary of Dr. Lok's presentation during the 2015 AGA Spring Postgraduate Course at DDW® 2015 in Washington, DC.

Clinical snapshots are free to AGA members. Please log in and "purchase" the free module to add it to your account. You will then have access to the full content of the summary on this same page whenever you are logged into the website.


1. Learn efficacy and limitations of currently approved treatments for hepatitis B.

2. Understand when to start and when to stop treatment.

3. Learn about the prospects for a cure.

About the Instructors

Anna S.F. Lok, MD, AGAF, University of Michigan

This is only a preview. Full access is reserved for AGA members. Login or learn more about becoming a member.

Efficacy and Limitations of Currently Approved Treatments

There are seven approved therapies: two formulations of interferon and five nucleos/tide analogues: lamivudine, telbivudine, entecavir, adefovir and tenofovir 1, 2. Although these drugs are effective in suppressing hepatitis B virus (HBV) replication, the rates of clearance of hepatitis B e antigen (HBsAg) and hepatitis B surface antigen (HBsAg) are low. Nevertheless, antiviral therapy for hepatitis B had been shown not only to reduce hepatic inflammation but also to reverse fibrosis and even cirrhosis …

More on Hepatitis C

Building Foundations Among Payers & Providers for Collaborative Care in HCV & HIV

Dec. 7, 2017

In this video, leading experts in HCV, HIV, and managed care engage in a crossfire panel discussion on key challenges, considerations and solutions for improving patient management, and appropriate access to HCV and HIV therapies.

Translating Basic Science Into Clinical Application

Dec. 7, 2017

The CMGH editors summarize five recently accepted studies in four sentences or less.

Experts Update HCV Treatment and Care Guidelines

Nov. 9, 2017

Revision adds newly approved treatments and recommendations for special populations.